Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

Current Medical Research and Opinion 2017.  June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis.
Curr Med Res Opin. 2014 Jun;30(6):1131-7. doi: 10.1185/03007995.2014.882299. Epub 2014 Jan 30.2:3. Background and objectives: Barrier-enforcing measures have been suggested as treatment options for allergic rhinitis. This review identifies and describes the literature on the subject.
Paediatr Drugs. 2016 Dec 20. doi: 10.1007/s40272-016-0207-z Background:
Adiarin®  is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia.
Following the publication of the experimental study by Fraile B et al.
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.
UTIPRO® PLUS AF Utipro® Plus AF is intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot.
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it is already present in Sweden, Norway and Finland, distributed as well by our partner RFSU.